Evidence map›Paper›PMID 28735353›Full record

ReviewCurrent neurology and neuroscience reports2017

Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.

Sujan T Reddy, T C Cossey, Sean I Savitz, James C Grotta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sujan T ReddyUniversity of Texas Health Science Center At Houston, 6431 Fannin, MSB 7.044, Houston, TX, 77030, USA. Sujan.T.Reddy@uth.tmc.edu.ORCID http://orcid.org/0000-0001-7454-114X
T C CosseyUniversity of Texas Health Science Center At Houston, 6431 Fannin, MSB 7.044, Houston, TX, 77030, USA.
Sean I SavitzUniversity of Texas Health Science Center At Houston, 6431 Fannin, MSB 7.044, Houston, TX, 77030, USA.
James C GrottaMemorial Hermann Hospital, Houston, TX, USA.
The University of Texas Health Science Center at Houston · USMemorial Hermann · USThe University of Texas Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAn 80-year-old man presents with an acute right hemiparesis and National Institutes of Health Stroke Scale (NIHSS) of 25, 14 h after taking dabigatran. Activated partial thromboplastin time (aPTT) is 42.8 s. Arteriogram demonstrates left internal carotid artery thrombosis. What is the appropriate management of this patient with acute ischemic stroke while on a NOAC? RECENT

findingsIdarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs. In this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.

Indexed as

Vitamin KAdministration, OralAntibodies, Monoclonal, HumanizedAnticoagulantsDabigatranFactor XaHemorrhageHumansRecombinant ProteinsStrokeThrombolytic TherapyAntibodies, Monoclonal, HumanizedAnticoagulantsDabigatranFactor XaidarucizumabPRT064445Recombinant ProteinsVitamin KAntidote for NOACNewer oral anticoagulantsNOACNVAFReversal agentsStroke

Identifiers

PMID28735353
OpenAlexW2736988336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.